SynthesisAlimentary pharmacology & therapeutics2017
Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
Synthesis in Alimentary pharmacology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Assessment of Barriers and Facilitators to the Delivery of Care for Noncommunicable Diseases by Nonphysician Health Workers in Low- and Middle-Income Countries: A Systematic Review and Qualitative Analysis.JAMA network open · 2019Pooled it
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.The American journal of gastroenterology · 2019Pooled it
- Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis.Inflammatory bowel diseases · 2026Trial
- The Proctitis Paradox: Refractory Ulcerative Proctitis Associated With Development of Disease Complications in a Multicenter South Australian Cohort.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Extending Knowledge: The Case for Treat-to-Target Management in Patients with Ulcerative Colitis Who Fail Early Treatment.Digestive diseases and sciences · 2026Article
- Initial Treatment Failure as a Predictor of Proximal Extension in Patients with Newly Diagnosed Limited Ulcerative Colitis: A Retrospective Cohort Study with Propensity Score-Matched Analysis.Digestive diseases and sciences · 2026Article
- Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts.Gastroenterology report · 2026Review
- Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States.Therapeutic advances in gastroenterology · 2026Article
- Inflammatory Bowel Disease Outcomes in Northern Iran: A Retrospective Cohort Study of Remission, Complications, and Treatment Strategies.BioMed research international · 2026Article
- Predictive Factors of Cytomegalovirus Colonic Reactivation in Patients with Active Ulcerative Colitis.Viruses · 2025Article
- Progression of Disease When Mesalamine Fails.Gastroenterology & hepatology · 2025Article
- Progressing or preserving, disease extent evolution in hospitalized patients with ulcerative colitis in China: a real-world study.Therapeutic advances in gastroenterology · 2025Article
- Natural history and progression risk factors of ulcerative proctitis: a retrospective study from a single tertiary centre in Poland.Przeglad gastroenterologiczny · 2025Article
- Separating Infectious Proctitis from Inflammatory Bowel Disease-A Common Clinical Conundrum.Microorganisms · 2024Review
- Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials.EClinicalMedicine · 2024Article
- Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus.Nature reviews. Gastroenterology & hepatology · 2024Review
- Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey.Journal of clinical medicine · 2024Article
- Disease clearance in ulcerative colitis: A new therapeutic target for the future.World journal of gastroenterology · 2024Article
- Identification of immune-associated genes for the diagnosis of ulcerative colitis-associated carcinogenesis via integrated bioinformatics analysis.Frontiers in oncology · 2024Article
- The Role of the Microbiome in the Pathogenesis and Treatment of Ulcerative Colitis-A Literature Review.Biomedicines · 2023Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 4 countries.
Funding
Abstract
backgroundDisease extent in ulcerative colitis is one of the major factors determining prognosis over the long-term. Disease extent is dynamic and a proportion of patients presenting with limited disease progress to more extensive forms of disease over time.
aimTo perform a systematic review and meta-analysis of epidemiological studies reporting on extension of ulcerative colitis to determine frequency of disease extension in patients with limited ulcerative colitis at diagnosis.
methodsWe performed a systematic literature search to identify studies on disease extension of ulcerative colitis (UC) and predictors of disease progression.
resultsOverall, 41 studies were eligible for systematic review but only 30 for meta-analysis. The overall pooled frequency of UC extension was 22.8% with colonic extension being 17.8% at 5 years and 31% at 10 years. Extension was 17.8% (95% CI 11.2-27.3) from E1 to E3, 27.5% (95% CI 7.6-45.6) from E2 to E3 and 20.8% (95% CI 11.4-26.8) from E1 to E2. Rate of extension was significantly higher in patients younger than 18 years (29.2% (CI 6.4-71.3) compared to older patients (20.2% (CI 13.0-30.1) (P<.0001). Risk of extension was significantly higher in patients from North America (37.8%) than from Europe (19.6%) (P<.0001).
conclusionsIn this meta-analysis, approximately one quarter of patients with limited UC extend over time with most extension occurring during the first 10 years. Rate of extension depends on age at diagnosis and geographic origin. Predicting those at high risk of disease extension from diagnosis could lead to personalised therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.